Yousif Capital Management LLC Sells 2,994 Shares of Envista Holdings Co. (NYSE:NVST)

Yousif Capital Management LLC cut its holdings in Envista Holdings Co. (NYSE:NVST) by 4.6% during the 4th quarter, Holdings Channel reports. The firm owned 62,315 shares of the company’s stock after selling 2,994 shares during the period. Yousif Capital Management LLC’s holdings in Envista were worth $1,202,000 at the end of the most recent quarter.

A number of other hedge funds also recently bought and sold shares of the business. Mirae Asset Global Investments Co. Ltd. purchased a new position in shares of Envista during the 3rd quarter worth approximately $31,000. GAMMA Investing LLC grew its holdings in Envista by 69.8% in the third quarter. GAMMA Investing LLC now owns 1,766 shares of the company’s stock worth $35,000 after purchasing an additional 726 shares during the period. Huntington National Bank increased its stake in shares of Envista by 97.8% during the third quarter. Huntington National Bank now owns 1,919 shares of the company’s stock valued at $38,000 after purchasing an additional 949 shares in the last quarter. Blue Trust Inc. lifted its holdings in shares of Envista by 69.7% during the third quarter. Blue Trust Inc. now owns 1,957 shares of the company’s stock valued at $39,000 after purchasing an additional 804 shares during the last quarter. Finally, Allspring Global Investments Holdings LLC boosted its position in shares of Envista by 50.8% in the 3rd quarter. Allspring Global Investments Holdings LLC now owns 2,161 shares of the company’s stock worth $43,000 after purchasing an additional 728 shares in the last quarter.

Analyst Ratings Changes

Several brokerages have recently issued reports on NVST. Stifel Nicolaus upped their target price on shares of Envista from $18.00 to $21.00 and gave the stock a “buy” rating in a research note on Wednesday, October 23rd. Piper Sandler upped their price target on Envista from $17.00 to $18.00 and gave the company a “neutral” rating in a report on Monday, February 3rd. Mizuho assumed coverage on Envista in a research report on Wednesday, December 4th. They set an “underperform” rating and a $20.00 price objective on the stock. Morgan Stanley boosted their target price on Envista from $19.00 to $20.00 and gave the stock an “equal weight” rating in a research report on Thursday, February 6th. Finally, Leerink Partnrs raised shares of Envista from a “strong sell” rating to a “hold” rating in a report on Thursday, October 31st. Two investment analysts have rated the stock with a sell rating, nine have issued a hold rating and three have assigned a buy rating to the company’s stock. According to MarketBeat.com, Envista currently has an average rating of “Hold” and a consensus price target of $20.21.

Envista Price Performance

Shares of NYSE:NVST opened at $21.49 on Friday. The company has a market capitalization of $3.70 billion, a P/E ratio of -3.31, a P/E/G ratio of 2.06 and a beta of 1.34. Envista Holdings Co. has a 1-year low of $15.15 and a 1-year high of $23.06. The firm’s 50 day simple moving average is $19.90 and its two-hundred day simple moving average is $19.28. The company has a debt-to-equity ratio of 0.44, a current ratio of 2.04 and a quick ratio of 1.77.

Envista (NYSE:NVST) last posted its quarterly earnings results on Wednesday, February 5th. The company reported $0.24 EPS for the quarter, topping analysts’ consensus estimates of $0.23 by $0.01. Envista had a positive return on equity of 3.86% and a negative net margin of 44.56%. Research analysts expect that Envista Holdings Co. will post 1.06 EPS for the current fiscal year.

Envista Profile

Envista Holdings Corporation, together with its subsidiaries, develops, manufactures, markets, and sells dental products in the United States, China, and internationally. The company operates in two segments, Specialty Products & Technologies, and Equipment & Consumables. The Specialty Products & Technologies segment offers dental implant systems, guided surgery systems, biomaterials, and prefabricated and custom-built prosthetics to oral surgeons, prosthodontists and periodontists, and general dentist; and brackets and wires, tubes and bands, archwires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products.